Astellas Pharma Valuation
| ALPMY Stock | USD 10.05 0.02 0.20% |
At this time, the firm appears to be overvalued. Astellas Pharma shows a prevailing Real Value of $8.99 per share. The current price of the firm is $10.05. Our model approximates the value of Astellas Pharma from analyzing the firm fundamentals such as Current Valuation of 26.19 B, return on equity of 0.0898, and Profit Margin of 0.09 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Astellas Pharma's price fluctuation is not too volatile at this time. Calculation of the real value of Astellas Pharma is based on 3 months time horizon. Increasing Astellas Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Astellas Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Astellas Pink Sheet. However, Astellas Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.05 | Real 8.99 | Hype 10.05 | Naive 9.65 |
The intrinsic value of Astellas Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Astellas Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Astellas Pharma helps investors to forecast how Astellas pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Astellas Pharma more accurately as focusing exclusively on Astellas Pharma's fundamentals will not take into account other important factors: Astellas Pharma Total Value Analysis
Astellas Pharma is presently expected to have takeover price of 26.19 B with market capitalization of 26.53 B, debt of 4.87 B, and cash on hands of 336.76 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Astellas Pharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
26.19 B | 26.53 B | 4.87 B | 336.76 B |
Astellas Pharma Investor Information
The book value of the company was presently reported as 861.58. The company last dividend was issued on the 29th of September 2022. Astellas Pharma had 125:100 split on the 2nd of April 2014. Based on the key measurements obtained from Astellas Pharma's financial statements, Astellas Pharma is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Astellas Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Astellas Pharma has an asset utilization ratio of 55.57 percent. This suggests that the Company is making $0.56 for each dollar of assets. An increasing asset utilization means that Astellas Pharma is more efficient with each dollar of assets it utilizes for everyday operations.Astellas Pharma Ownership Allocation
Astellas Pharma holds a total of 1.83 Billion outstanding shares. Almost 99.97 percent of Astellas Pharma outstanding shares are held by general public with 0.03 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Astellas Pharma Profitability Analysis
The company reported the revenue of 1.3 T. Net Income was 124.09 B with profit before overhead, payroll, taxes, and interest of 1.04 T.About Astellas Pharma Valuation
Our relative valuation model uses a comparative analysis of Astellas Pharma. We calculate exposure to Astellas Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Astellas Pharma's related companies.Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 14522 people.
8 Steps to conduct Astellas Pharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Astellas Pharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Astellas Pharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Astellas Pharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Astellas Pharma's revenue streams: Identify Astellas Pharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Astellas Pharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Astellas Pharma's growth potential: Evaluate Astellas Pharma's management, business model, and growth potential.
- Determine Astellas Pharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Astellas Pharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Astellas Pharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1.9 B | |
| Quarterly Earnings Growth Y O Y | -0.192 | |
| Forward Price Earnings | 15.748 | |
| Retained Earnings | 944.3 B |
Additional Tools for Astellas Pink Sheet Analysis
When running Astellas Pharma's price analysis, check to measure Astellas Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astellas Pharma is operating at the current time. Most of Astellas Pharma's value examination focuses on studying past and present price action to predict the probability of Astellas Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astellas Pharma's price. Additionally, you may evaluate how the addition of Astellas Pharma to your portfolios can decrease your overall portfolio volatility.